Skip to main content

Advertisement

SpringerLink
Log in

Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Intrahepatic cholangiocarcinoma (ICC) is an aggressive biliary tract cancer (BTC) that arises from the biliary tract epithelium distal to the secondary biliary radicals. Over the past decade, significant advances have been made in the diagnosis, staging, and treatment of ICC. Emerging data have highlighted the importance of lymphadenectomy for elucidating patient prognosis as well as the at-risk nodal basins based on tumor location (de Jong et al. in J Clin Oncol 29(23):3140–3145, 2011). Several large randomized controlled trials have recently been published clarifying the role of adjuvant therapy for BTCs (Cloyd and Pawlik in J Oncol Pract 14(12):723–724, 2018). In addition, the molecular understanding of ICC pathogenesis has increased over time, leading to new potential molecular biomarkers and opening opportunities for novel targeted and immunologic therapies (Rizvi et al. in Nat Rev Clin Oncol 15(2):95–111, 2018). These recent advances serve to only improve our understanding of the optimal multidisciplinary treatment of this difficult disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Reproduced from Shimada et al.,54 with permission

Fig. 2

Reproduced from Moeini et al.,67 with permission

References

  1. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221–32.

    PubMed  Google Scholar 

  2. Beal EW, Tumin D, Moris D, Zhang XF, Chakedis J, Dilhoff M, et al. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2018;7(4):270–6.

    PubMed  PubMed Central  Google Scholar 

  3. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565–74.

    PubMed  Google Scholar 

  4. Spolverato G, Vitale A, Cucchetti A, Popescu I, Marques HP, Aldrighetti L, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer. 2015;121(22):3998–4006.

    PubMed  Google Scholar 

  5. Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(1):14–22.

    PubMed  Google Scholar 

  6. Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer. 2011;117(10):2170–7.

    PubMed  Google Scholar 

  7. de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–5.

    PubMed  Google Scholar 

  8. Cloyd JM, Pawlik TM. Adjuvant therapy for biliary tract cancers: new evidence to resolve old questions. J Oncol Pract. 2018;14(12):723–4.

    PubMed  Google Scholar 

  9. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111.

    CAS  PubMed  Google Scholar 

  10. Edge SB, Byrd DR, Compton CC, et al. (eds). AJCC cancer staging manual. 8th ed. New York: Springer; 2017.

    Google Scholar 

  11. Chen Z, Guo P, Xie X, Yu H, Wang Y, Chen G. The role of tumour microenvironment: a new vision for cholangiocarcinoma. J Cell Mol Med. 2019;23(1):59–69.

    PubMed  Google Scholar 

  12. Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, et al. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1435–43.

    CAS  PubMed  Google Scholar 

  13. Andersen JB. Molecular pathogenesis of intrahepatic cholangiocarcinoma. J Hepato-Biliary-Pancreat Sci. 2015;22(2):101–13.

    Google Scholar 

  14. Rahnemai-Azar AA, Weisbrod A, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol. 2017;26(2):125–37.

    PubMed  Google Scholar 

  15. Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S. Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget. 2015;6(17):14744–53.

    PubMed  PubMed Central  Google Scholar 

  16. Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019;19(1):185.

    PubMed  PubMed Central  Google Scholar 

  17. Fabrega-Foster K, Ghasabeh MA, Pawlik TM, Kamel IR. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(2):67–78.

    PubMed  PubMed Central  Google Scholar 

  18. Liang B, Zhong L, He Q, Wang S, Pan Z, Wang T, et al. Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis. Med Sci Monit. 2015;21:3555–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Zhou J, Liu Z, Yang S, Li X. Identification of microRNAs as biomarkers for cholangiocarcinoma detection: a diagnostic meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(2):156–62.

    CAS  PubMed  Google Scholar 

  20. Xuan J, Li J, Zhou Z, Zhou R, Xu H, Wen W. The diagnostic performance of serum MUC5AC for cholangiocarcinoma: a systematic review and meta-analysis. Medicine. 2016;95(24):e3513.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Haga H, Patel T. Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepato-Biliary-Pancreat Sci. 2015;22(2):114–23.

    Google Scholar 

  22. Tannapfel A, Weinans L, Geissler F, Schutz A, Katalinic A, Kockerling F, et al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci. 2000;45(2):317–24.

    CAS  PubMed  Google Scholar 

  23. Spolverato G, Yakoob MY, Kim Y, Alexandrescu S, Marques HP, Lamelas J, et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2015;22(12):4020–8.

    PubMed  Google Scholar 

  24. Sirica AE. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14(46):7033–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43(10):1552–8.

    CAS  PubMed  Google Scholar 

  26. Chen TC, Jan YY, Yeh TS. K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy. Ann Surg Oncol. 2012;19(Suppl 3):S675–81.

    PubMed  Google Scholar 

  27. Chen Y, Ma L, He Q, Zhang S, Zhang C, Jia W. TGF-beta1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. Biol Res. 2015;48:26.

    PubMed  PubMed Central  Google Scholar 

  28. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998;29(2):175–80.

    CAS  PubMed  Google Scholar 

  29. Huang SB, Zheng CX. Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma. Expert Rev Anticancer Ther. 2017;17(1):89–96.

    CAS  PubMed  Google Scholar 

  30. Chen L, Yan HX, Yang W, Hu L, Yu LX, Liu Q, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 2009;50(2):358–69.

    CAS  PubMed  Google Scholar 

  31. Matsumura N, Yamamoto M, Aruga A, Takasaki K, Nakano M. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer. 2002;94(6):1770–6.

    PubMed  Google Scholar 

  32. Miwa S, Miyagawa S, Soeda J, Kawasaki S. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer. 2002;94(2):428–34.

    CAS  PubMed  Google Scholar 

  33. Cloyd JM, Chun YS, Ikoma N, Vauthey JN, Aloia TA, Cuddy A, et al. Clinical and genetic implications of DNA mismatch repair deficiency in biliary tract cancers associated with lynch syndrome. J Gastrointest Cancer. 2018;49(1):93–6.

    CAS  PubMed  Google Scholar 

  34. Yang JD, Campion MB, Liu MC, Chaiteerakij R, Giama NH, Ahmed Mohammed H, et al. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology. 2016;63(1):148–58.

    PubMed  Google Scholar 

  35. Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, Fazio N, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 2017;36(1):141–57.

    CAS  PubMed  Google Scholar 

  36. Gani F, Nagarajan N, Kim Y, Zhu Q, Luan L, Bhaijjee F, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2016;23(8):2610–7.

    PubMed  Google Scholar 

  37. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68(5):959–69.

    CAS  PubMed  Google Scholar 

  40. Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Goeppert B, Toth R, Singer S, Albrecht T, Lipka DB, Lutsik P, et al. Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. Hepatology. 2019;69(5):2091–106.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Fujita N, Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y, et al. Mass-forming intrahepatic cholangiocarcinoma: enhancement patterns in the arterial phase of dynamic hepatic CT—correlation with clinicopathological findings. Eur Radiol. 2017;27(2):498–506.

    PubMed  Google Scholar 

  43. Lee J, Kim SH, Kang TW, Song KD, Choi D, Jang KT. Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging as a preoperative prognostic marker. Radiology. 2016;281(1):119–28.

    PubMed  Google Scholar 

  44. Park MS, Lee SM. Preoperative 18F-FDG PET-CT maximum standardized uptake value predicts recurrence of biliary tract cancer. Anticancer Res. 2014;34(5):2551–4.

    PubMed  Google Scholar 

  45. Lewis HL, Ghasabeh MA, Khoshpouri P, Kamel IR, Pawlik TM. Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. Surg Oncol. 2017;26(4):411–22.

    CAS  PubMed  Google Scholar 

  46. Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, et al. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology. 2012;264(1):285–94.

    PubMed  Google Scholar 

  47. Pandey A, Pandey P, Aliyari Ghasabeh M, Najmi Varzaneh F, Shao N, Khoshpouri P, et al. Unresectable intrahepatic cholangiocarcinoma: multiparametric MR imaging to predict patient survival. Radiology. 2018;288(1):109–17.

    PubMed  Google Scholar 

  48. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193(4):384–91.

    CAS  PubMed  Google Scholar 

  49. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–62.

    PubMed  PubMed Central  Google Scholar 

  50. Yoh T, Hatano E, Seo S, Okuda Y, Fuji H, Ikeno Y, et al. Long-term survival of recurrent intrahepatic cholangiocarcinoma: the impact and selection of repeat surgery. World J Surg. 2018;42(6):1848–56.

    PubMed  Google Scholar 

  51. Kim Y, Spolverato G, Amini N, Margonis GA, Gupta R, Ejaz A, et al. Surgical management of intrahepatic cholangiocarcinoma: defining an optimal prognostic lymph node stratification schema. Ann Surg Oncol. 2015;22(8):2772–8.

    PubMed  Google Scholar 

  52. Ronnekleiv-Kelly SM, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):35–43.

    PubMed  PubMed Central  Google Scholar 

  53. Okami J, Dono K, Sakon M, Tsujie M, Hayashi N, Fujiwara Y, et al. Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe. J Gastrointest Surg. 2003;7(7):850–6.

    PubMed  Google Scholar 

  54. Shimada M, Yamashita Y, Aishima S, Shirabe K, Takenaka K, Sugimachi K. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg. 2001;88(11):1463–6.

    CAS  PubMed  Google Scholar 

  55. Reames BN, Ejaz A, Koerkamp BG, Alexandrescu S, Marques HP, Aldrighetti L, et al. Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. J Surg Oncol. 2017;116(2):133–9.

    PubMed  Google Scholar 

  56. Zhang XF, Bagante F, Chakedis J, Moris D, Beal EW, Weiss M, et al. Perioperative and long-term outcome for intrahepatic cholangiocarcinoma: impact of major versus minor hepatectomy. J Gastrointest Surg. 2017;21(11):1841–50.

    PubMed  Google Scholar 

  57. Si A, Li J, Xing X, Lei Z, Xia Y, Yan Z, et al. Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: factors associated with long-term outcomes. Surgery. 2017;161(4):897–908.

    PubMed  Google Scholar 

  58. Souche R, Addeo P, Oussoultzoglou E, Herrero A, Rosso E, Navarro F, et al. First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma. Am J Surg. 2016;212(2):221–9.

    PubMed  Google Scholar 

  59. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513–8.

    CAS  PubMed  Google Scholar 

  60. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

    CAS  PubMed  Google Scholar 

  61. Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658-67.

    CAS  PubMed  Google Scholar 

  62. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–673.

    CAS  PubMed  Google Scholar 

  63. Konstantinidis IT, Groot Koerkamp B, Do RK, Gonen M, Fong Y, Allen PJ, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758–65.

    PubMed  Google Scholar 

  64. Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21(12):3827–34.

    PubMed  PubMed Central  Google Scholar 

  65. Massard C, Michiels S, Ferte C, Le Deley MC, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586–95.

    CAS  PubMed  Google Scholar 

  66. Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–10.

    CAS  PubMed  Google Scholar 

  67. Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin Cancer Res. 2016;22(2):291–300.

    PubMed  Google Scholar 

  68. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069–74.

    CAS  PubMed  Google Scholar 

  69. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11(12):1142–8.

    CAS  PubMed  Google Scholar 

  70. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardiere C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–82.

    CAS  PubMed  Google Scholar 

  72. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.

    PubMed  PubMed Central  Google Scholar 

  73. Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165–71.

    CAS  PubMed  Google Scholar 

  74. Kalyukina M, Yosaatmadja Y, Middleditch MJ, Patterson AV, Smaill JB, Squire CJ. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem. 2019;14(4):494–500.

    CAS  PubMed  Google Scholar 

  75. Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013;32(41):4861–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010;28(21):3491–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54.

    CAS  PubMed  Google Scholar 

  78. Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol. 2015;21(7):2096–101.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist. 2018;23(12):1407-e136.

    PubMed  PubMed Central  Google Scholar 

  80. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol. 2007;73(9):1308–17.

    CAS  PubMed  Google Scholar 

  81. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012;30(4):1646-51.

    CAS  PubMed  Google Scholar 

  82. Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019;125(6):902–9.

    CAS  PubMed  Google Scholar 

  83. Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S, et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer. 2009;100(8):1257–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, et al. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017;123(11):1979–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res. 2007;13(16):4795–9.

    CAS  PubMed  Google Scholar 

  86. Silva VW, Askan G, Daniel TD, Lowery M, Klimstra DS, Abou-Alfa GK, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol. 2016;5(5):62.

    PubMed  Google Scholar 

  87. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. James Cancer Center, The Ohio State University, Columbus, OH, USA

    Aslam Ejaz MD, MPH, Jordan M. Cloyd MD & Timothy M. Pawlik MD, MPH, PhD

  2. Wexner Medical Center, The Ohio State University, Columbus, OH, USA

    Aslam Ejaz MD, MPH

Authors
  1. Aslam Ejaz MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jordan M. Cloyd MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy M. Pawlik MD, MPH, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aslam Ejaz MD, MPH.

Ethics declarations

Disclosure

Aslam Ejaz, Jordan M. Cloyd, and Timothy M. Pawlik have no conflicts of interest to report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ejaz, A., Cloyd, J.M. & Pawlik, T.M. Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 27, 552–560 (2020). https://doi.org/10.1245/s10434-019-07873-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-07873-z

Search

Navigation